Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Clin Cancer Res. 2018 Aug 6;24(23):5883–5894. doi: 10.1158/1078-0432.CCR-17-3668

Fig 4.

Fig 4.

Clinical outcomes associated with low and high delta tumors. (A) (Left) Proportions of low and high delta tumors in patients with metastatic PDAC at presentation (Fisher’s exact test, P=0.03; patient characteristics shown in Supplementary Table S4). (Right) Proportions of low and high delta tumors in patients with early-stage, localized PDAC (patient characteristics in Supplementary Table S2). (B) (Left) Distant metastasis-free survival (DMFS) stratified by delta measurement for patients in Supplementary Table S2. (Right) DMFS stratified by delta measurement for patients in Supplementary Table S3. (C) (Left) Overall survival (OS) stratified by delta measurement for patients in Supplementary Table S2. (Right) OS stratified by delta measurement for patients in Supplementary Table S3.